Join Our Newsletter

Polydex Pharmaceuticals Ltd. - POLXF

RSI %R Tweets Wolf Odds
79 0 0 32.825%

Industry: Biotechnology / Sector: Healthcare



Prev Close: 1.23
Open: 1.2300
Last Trade: 1.23
Change %: 0.000%
Change: 0.0000000
Volume: 0
Avg Vol: 1870
Relative Vol: 0.00
Day Range: 1.23 -1.23
52-Week Range:
Market Cap: 4.11M
Float: 2.86M
Shares Outstanding: 3.4M
Insider Owned: 0.00%
Institution Owned: 0.00%
Beta: -0.72
PE Ratio: 10.34
EPS: 0.12

POLXF Detailed Stats

RSI:79.17 %K:100.00 Wolf Odds: 32.825% Tweets Today:0 SMA14:1.1736
stochRSI:1.00 %D:88.89 Wolf Trend:0.00 Tweet Avg:0 Pivot Price:1.2300000
%R:0.00 %B:0.87 Wolf 3-Day:0.02 Avg. Change 3-Day:+1.120% Resistance 1:1.2300000
MFI:97.37 Bandwidth:0.130542 Wolf 7-Day:0.03 Avg. Change 7-Day:+0.977% Resistance 2:1.2300000
WolfPeak:0.95 Vortex Indicator:-0.46 Wolf 14-Day:0.06 Avg. Change 14-Day:+0.76% Support 1:1.2300000
ROC 7/14:6.9565/10.8108 Aroon Oscillator:85.7143 EOM:0.000000 Relative Vol:0.00 Support 2:1.2300000
RSI Alert:RSI Peak WolfPeak Alert:Near Peak Vortex Alert:None Aroon Alert:None EOM Alert:None

Featured News *


POLXF Description

Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

POLXF Comments

Recent POLXF Tweets

Powered by Ekonomys ver. 9

StockWolf is dedicated to Penny Stock quotes and data to provide information, news, and education on penny stocks to help in your due diligence.

30min+ delay on data. All data is picked with automated algorithms and not vetted for accuracy. Please, read ALL information and disclaimers before using our service. StockWolf is not a licensed financial adviser, and not liable for your loses. Trade responsibly. This site is for education purposes only not a recommendation to buy/sell